USA flag logo/image

An Official Website of the United States Government

Antiangiogenic and antitumoral therapy delivered by a dual-expression L.…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93516
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA137915
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADVAXIS, INC.
675 Highway one North Brunswick, NJ 08902 3378
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Antiangiogenic and antitumoral therapy delivered by a dual-expression L. monocyto
Agency: HHS
Contract: 1R43CA137915-01A1
Award Amount: $210,739.00
 

Abstract:

DESCRIPTION (provided by applicant): Breast cancer is the second most common type of cancer in females, causing over 40,000 deaths in the United States annually. Recently, cancer vaccines have arisen as a potential therapy and several target antigens have been identified in Breast cancer, including Her2/neu antigen. The goal of cancer vaccines is to generate effector T cells that are able to infiltrate and kill the tumor cells. We propose to generate a single recombinant Listeria monocytogenes capable of ta rgeting cancer cells and tumor vasculature by concomitant expression of Her2 and HMW-MAA, which is expressed in pericytes and plays a role in tumor angiogenesis. To address this challenge, a dual-expression Lm platform is created by expressing Her2 from th e chromosome and HMW-MAA from a plasmid. To enhance immunogenicity, both antigens are fused to the virulence factor listeriolysin-O and immune responses and therapeutic efficacy of the dual-expression system will be evaluated, including analysis of tumor-i nfiltrating lymphocytes and tumor vasculature. Delivery of an anti-angiogenic antigen simultaneously with a tumor-associated antigen will likely have a synergistic effect in impacting tumor growth by targeting blood vessels, which might enhance effector T cell infiltration in the tumor and improve the vaccine therapeutic efficacy, besides creating a flexible platform for future use. PUBLIC HEALTH RELEVANCE: Breast cancer is a major health problem in female population, causing the death of over 40,000 Ameri can men annually. In this SBIR Phase I project, Advaxis Inc. will construct a novel, clinically suitable recombinant Listeria monocytogenes capable of targeting Her2 expressing breast cancer cells and tumor vasculature concomitantly, which will be tested i n a mouse tumor model.

Principal Investigator:

Paulo C. Maciag
6093568307
PAULO.MACIAG@BMS.COM

Business Contact:


wallecha@advaxis.com
Small Business Information at Submission:

ADVAXIS, INC.
675 Highway one North Brunswick, NJ 08902

EIN/Tax ID: 020563870
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No